P/E - Friulchem SpA (MIL:FCM) - Alpha Spread

Friulchem SpA
MIL:FCM

Watchlist Manager
Friulchem SpA Logo
Friulchem SpA
MIL:FCM
Watchlist
Price: 0.765 EUR -1.92%
Market Cap: 6.1m EUR
Have any thoughts about
Friulchem SpA?
Write Note

P/E
Price to Earnings

-27.5
Current
82.2
Median
22.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-27.5
=
Market Cap
6.2m EUR
/
Net Income
-226.8k EUR
All Countries
Close
Market Cap P/E
IT
Friulchem SpA
MIL:FCM
6.2m EUR -27.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
853.5B USD 116.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
3.5T DKK 39.4
US
Johnson & Johnson
NYSE:JNJ
385.7B USD 10.1
US
Merck & Co Inc
NYSE:MRK
278.6B USD 20.3
UK
AstraZeneca PLC
NASDAQ:AZN
240B USD 37.3
CH
Roche Holding AG
SIX:ROG
207.1B CHF 18
CH
Novartis AG
SIX:NOVN
191.2B CHF 13.8
US
Pfizer Inc
NYSE:PFE
166.8B USD -64.2
Earnings Growth
IT
Friulchem SpA
MIL:FCM
Average P/E: 36.5
Negative Multiple: -27.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
116.4
425%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
39.4
90%
US
Johnson & Johnson
NYSE:JNJ
10.1
-22%
US
Merck & Co Inc
NYSE:MRK
20.3
7 419%
UK
A
AstraZeneca PLC
NASDAQ:AZN
37.3
175%
CH
Roche Holding AG
SIX:ROG
18
30%
CH
Novartis AG
SIX:NOVN
13.8
19%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -64.2
712%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-77.2
2-Years Forward
P/E
9.7
3-Years Forward
P/E
7

See Also

Discover More